We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 57.00 | 55.00 | 59.00 | 57.00 | 57.00 | 57.00 | 7,184 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 29.49M | -302k | -0.0043 | -132.56 | 40.23M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/4/2022 10:10 | A few more snips of info and presentations from the company will soon have a major positive impact. It is interesting to watch the MM game going on today and it seems the doors open once again. | clocktower | |
28/4/2022 07:55 | About Neil Hunt: Encouraging to have such a qualified participant. | cliffpeat | |
28/4/2022 07:54 | GSG, I am not surprised but I can only set my target on the research and information that I have received. However I do not doubt that you maybe correct, and I may up my target as more information and results becomes available, as this is now a longer term hold for me. MM keeping the lid shut this morning, I believe they may be very short of stock. | clocktower | |
28/4/2022 07:30 | clocktower. Having met the top team earlier this week, my target is double yours. | gsg | |
28/4/2022 07:11 | I like the way they have released this news, very understated. I expect it will soon attract the micro fund managers, as the presentation to such a massive market will have such a positive effect. I am now raising my target to 1p. I am pleased that I had another nibble yesterday . | clocktower | |
28/4/2022 06:54 | A massive market indeed for OrthoPure®XT. | gsg | |
28/4/2022 06:18 | A massive market that is cruciate ligament repair if this becomes the go to treatment it will be huge in its own right the war aspect could also be advents Gould to TRX | tnt99 | |
27/4/2022 09:02 | The sort of medical supplies TRX supplies must be in huge demand from the medics that have to treat the poor souls that are suffering from Russian aggression. I wonder if the international medical aid given to Ukraine would include many of the wound healing products produced by TRX? | clocktower | |
26/4/2022 15:58 | The US market dragging almost everything down today it seems, with this slipping on relatively small volume but with the notice of the results of the votes at the AGM out of the way, I expect that as soon as the market bucks up, we will see a rapid turnaround with some micro cap major investors giving this a good look over, and maybe adding it to their portfolios, as it looks well placed to move up quickly on any news of a good contract or two. | clocktower | |
25/4/2022 11:23 | Your nibble being bigger than mine today and a fraction cheaper mark. Well done. Don't forget The AGM will be held at DLA Piper, 160 Aldersgate St, Barbican, London EC1A 4HT, on Tuesday 26 April 2022 at 1.00pm. I guess the felling expressed will be very positive tomorrow. | clocktower | |
25/4/2022 11:01 | I thought I would have another little nibble, as its weak today 250k - 0.51 shows as a sell on ADVFN. Director buying the other day at over 0.54 with a good outlook. If it drops further, I go for another bite of the cherry. | clocktower | |
22/4/2022 07:05 | Another director buy good to see and could move the share back to 1p by Christmas still very cheap at the mo | tnt99 | |
21/4/2022 13:22 | I hope it gets there well before 5 years CarrotandStick. I am well in the Blue with this one, and will keep adding on weakness now. It would not surprise me to find out that another director is buying, as a few of the MM's have taken on a lot of stock before dropping the bid while still keeping the offer, to shake out a few more. So a little dip before the next big step and maybe news in May to help it on its way. | clocktower | |
21/4/2022 06:06 | I'm going to hold you to that Clocktower! | carrotandstick | |
20/4/2022 20:20 | 10 plus imo. The groundwork is done, the growth will flow. | clocktower | |
20/4/2022 16:56 | A few million shares for just a few thou, doesn't it make you want to buy some. I like the consensus that TRX has negotiated the bottom, prospects are all upwards from here, I would love to understand how big a market they could grow in to and at what margin. What I mean to ask, is the 3-5 year horizon x 2 or x 10? | marktime1231 | |
20/4/2022 15:28 | Another decent director buy. | clocktower | |
19/4/2022 12:27 | It's good to see the two way trade and a few larger blocks being sold, as profits are taken and a new platform of .53 - .55 is being built as a solid base before taking the next step up towards a first target of .70 There is plenty of PI support and as you say quazie12, if a couple of microcaps start building a stake this could move well past my first target quickly. Is there a chart expert following the thread that could comment on the recent and likely upward movement? | clocktower | |
19/4/2022 12:00 | Thanks for the link GSG - Great report and well worth reading in full. | clocktower | |
19/4/2022 10:31 | Just need a couple more microcap funds to start stake building as this moves towards ebitda breakevwn and profitability | quazie12 | |
19/4/2022 10:30 | They value coy on 4 * 2023 forecast revenues 90m sterling or roughly 1.25p | quazie12 | |
19/4/2022 06:43 | Hardman & Co Research on Tissue Regenix (TRX): On pathway to sustainability Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery, orthopaedics and dental markets. 2021 results contained the early benefits of TRX's strategic activities over the past two years - the focus on commercial relationships, capacity expansion, restructuring to service demand and recovery in elective surgeries. On the basis of continued sales progression, TRX is forecast to become EBITDA-positive in fiscal 2022 and cash-generative in 2023. Please click on the link below for the full report: | gsg | |
14/4/2022 12:30 | https://audioboom.co | bloomberg2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions